A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer
Titel:
A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer
Auteur:
O'Neil, B.H. Scott, A.J. Ma, W.W. Cohen, S.J. Leichman, L. Aisner, D.L. Menter, A.R. Tejani, M.A. Cho, J.K. Granfortuna, J. Coveler, L. Olowokure, O.O. Baranda, J.C. Cusnir, M. Phillip, P. Boles, J. Nazemzadeh, R. Rarick, M. Cohen, D.J. Radford, J. Fehrenbacher, L. Bajaj, R. Bathini, V. Fanta, P. Berlin, J. McRee, A.J. Maguire, R. Wilhelm, F. Maniar, M. Jimeno, A. Gomes, C.L. Messersmith, W.A.